The development and validation of the Leiden Bother and Needs Questionnaire for patients with pituitary disease: the LBNQ-Pituitary by Andela, C. D. et al.
              
City, University of London Institutional Repository
Citation: Andela, C. D., Scharloo, M., Ramondt, S., Tiemensma, J., Husson, O., Llahana, 
S. ORCID: 0000-0002-3606-5370, Pereira, A. M., Kaptein, A. A., Kamminga, N. G. A. and 
Biermasz, N. R. (2016). The development and validation of the Leiden Bother and Needs 
Questionnaire for patients with pituitary disease: the LBNQ-Pituitary. Pituitary, 19(3), pp. 
293-302. doi: 10.1007/s11102-016-0707-4 
This is the published version of the paper. 
This version of the publication may differ from the final published 
version. 
Permanent repository link:  http://openaccess.city.ac.uk/20964/
Link to published version: http://dx.doi.org/10.1007/s11102-016-0707-4
Copyright and reuse: City Research Online aims to make research 
outputs of City, University of London available to a wider audience. 
Copyright and Moral Rights remain with the author(s) and/or copyright 
holders. URLs from City Research Online may be freely distributed and 
linked to.
City Research Online:            http://openaccess.city.ac.uk/            publications@city.ac.uk
City Research Online
The development and validation of the Leiden Bother and
Needs Questionnaire for patients with pituitary disease:
the LBNQ-Pituitary
Cornelie D. Andela1 • Margreet Scharloo2 • Steven Ramondt3 • Jitske Tiemensma3 •
Olga Husson4 • Sofia Llahana5 • Alberto M. Pereira1 • Ad. A. Kaptein2 •
Noe¨lle G. A. Kamminga6 • Nienke R. Biermasz1
Published online: 25 January 2016
 The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract
Background Patients report persisting impairment in
quality of life (QoL) after treatment for pituitary disease.
At present, there is no questionnaire to assess (a) whether
patients with pituitary disease are bothered by these con-
sequences, and (b) their needs for support.
Objective To develop and validate a disease-specific
questionnaire for patients with pituitary disease which
incorporates patient perceived bother related to the con-
sequences of the disease, and their needs for support.
Methods Items for the Leiden Bother and Needs Ques-
tionnaire for patients with pituitary disease (LBNQ-Pitu-
itary) were formulated based on results of a recent focus
group study (n = 49 items). 337 patients completed the
LBNQ-Pituitary and six validated QoL questionnaires
(EuroQoL-5D, SF-36, MFI-20, HADS, AcroQol, Cush-
ingQoL). Construct validity was examined by exploratory
factor analysis. Reliabilities of the subscales were calcu-
lated with Cronbach’s alphas, and concurrent validity was
assessed by calculating Spearman’s correlations between
the LBNQ-Pituitary and the other measures.
Results Factor analyses produced five subscales (i.e.,
mood problems, negative illness perceptions, issues in
sexual functioning, physical and cognitive complaints,
issues in social functioning) containing a total of 26 items.
All factors were found to be reliable (Cronbach’s alphas all
C.765), and the correlations between the dimensions of the
LBNQ-Pituitary and other questionnaires (all P B .0001)
demonstrated convergent validity.
Conclusions The LBNQ-Pituitary can be used to assess the
degree to which patients are bothered by the consequences of
the pituitary disease, as well as their needs for support. It could
also facilitate an efficient assessment of patients’ needs for
support in clinical practice. We postulate that paying attention
to needs for support will lead to optimal patient care (e.g.,
improvement in psychosocial care), and positively affect QoL.
Keywords Patient-reported-outcome  Needs  Quality of
life  Illness perceptions  Pituitary adenomas 
Acromegaly  Cushing’s disease  Cushing’s syndrome 
Prolactinoma  Non-functioning pituitary macroadenoma 
Hypopituitarism
Introduction
Pituitary adenomas can cause several symptoms in the
physical, psychological, and social domain, and can be
treated by surgery, drug treatment or additional
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radiotherapy. Symptoms can (partly) resolve upon treat-
ment, but many patients will have permanent hypopitu-
itarism and will require life-long multiple hormone
replacement therapy and/or will experience remaining
symptoms [1]. In line with these findings, research in
patients with pituitary diseases demonstrated that patients
report Quality of Life (QoL) impairments [2], also after
long-term remission [3–6]. The increasing number of QoL
studies in patients with pituitary disease suggests a growing
interest in the patient’s perspective [7]. QoL in patients
with pituitary disease has been mainly evaluated by generic
QoL questionnaires assessing several domains, disease-
specific QoL questionnaires assessing disease related QoL
aspects, or domain-specific questionnaires assessing par-
ticular domain(s) of QoL. Disease-specific QoL question-
naires for pituitary diseases are available for Cushing’s
syndrome (i.e., CushingQoL, Tuebing CD-25 [8–10]),
acromegaly (AcroQoL [11–13]) and growth-hormone
deficiency (QoL-AGHDA [14]), whereas no questionnaires
are available for patients with non-functioning pituitary
adenoma or prolactinoma.
Recently, we performed a qualitative study utilizing
focus group interviews in patients with pituitary diseases in
order to further explore the patient’s perspective on QoL
[15]. Issues raised in these conversations were compatible
with items of available questionnaires, but other topics also
emerged. New issues raised that are not covered in existing
questionnaires were visual problems, fear of recurrence of
the pituitary adenoma, problems with an altered personal-
ity, and lack of sympathy and understanding by others.
Furthermore, patients reported unmet needs regarding care,
such as dissatisfaction with other aspects of medical care
i.e., psychological support [15]. In contrast to the large
number of studies measuring QoL in patients with pituitary
disease, only few studies suggest strategies to improve QoL
[7]. Exploration of the patient’s perspective is crucial in
identifying potential unmet needs and aspects for
improvement in QoL.
Therefore, the aim of the present study was to develop
and validate a new questionnaire aiming to assess the
degree to which patients are bothered by the consequences
of their pituitary disease, as well as their needs for support.
The patient’s perspective elucidated during the focus group
conversations [15] formed the basis for the development of
this questionnaire.
Patients and methods
Patients
Patients between 18 and 80 years old with a pituitary dis-
ease [i.e., Cushing’s disease (CD), acromegaly (ACRO),
prolactinoma (PRL), and non-functioning adenoma (NFA)]
monitored at our institute were invited by letter for this
study (N = 554). Those who did not respond were con-
tacted by phone and encouraged to participate. A response
was received from 408 patients (74 %), but sixty-one of
them (15 %) denoted that they did not want to participate.
Main reported reasons for not participating were language
barrier or perceiving the questionnaire as being too time
consuming. Eventually, 347 (63 %) patients completed the
questionnaires. Of these, 10 patients filled out\75 % of
the LBNQ-Pituitary and were excluded from the analyses,
resulting in a total number of 337 (61 %) patients for
inclusion. Clinical characteristics of patients were derived
from medical records.
Diagnosis, treatment and follow-up
Details on diagnostic criteria and criteria for remission and
follow-up have been previously described: CD [16], ACRO
[3], PRL [5], NFA [17]. Essentially, international guideli-
nes for diagnosis, management were followed. At the time
of the current study, all patients were in remission or well
controlled with medical treatment regimens.
Procedure
All patients were asked to complete our newly developed
questionnaire (see next paragraph), two generic QoL
questionnaires and two domain-specific questionnaires. In
addition, patients with CD or ACRO were also asked to fill
out a disease-specific QoL questionnaire (CushingQoL or
AcroQoL, respectively). Based on the preference of the
patient, questionnaires were sent by email (online survey)
or by regular mail, in order to increase response rate. 255
patients completed the questionnaire online, 82 patients by
postal survey. Previous research demonstrated that paper-
and-pencil and online surveys did not lead to different
results [18]. The Medical Ethical Committee of the LUMC
approved this study.
Development of LBNQ-Pituitary
The items of the Leiden Bother and Needs Questionnaire
for patients with Pituitary disease (LBNQ-Pituitary) were
derived from recent focus group conversations [15]. The
format of the LBNQ-Pituitary was based on the ‘‘Belas-
tungsfragebogen Parkinson kurzversion (BELA-P-k)’’
(Questionnaire on psychosocial Burden and Needs for help
in Parkinson’s disease) [19], which has been found to be
valid and reliable for Dutch patients with Parkinson’s
disease [20].
Consequently, each item consists of three parts. Part A)
a screening question to ask whether a certain complaint is
294 Pituitary (2016) 19:293–302
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present (Yes/To a certain extent/No). For some questions
regarding fertility, their family or their partner, patients
could also indicate ‘‘Not applicable’’. Part B) a question on
the extent by which the patients is bothered by the com-
plaint (Bothered by (Bb)). Part C) a question to assess how
much importance patients place on the attention form their
healthcare provider for their complaint [Needs for Support
(NfS)]. Part B and C were scored on a 5-point Likert scale
(0 = ‘‘not at all’’ to 4 = ‘‘extremely’’) and (0 = ‘‘not
important’’ to 4 = ‘‘extremely important’’).
The initial LBNQ-Pituitary consisted of 49 items and
one open-ended question (Supplement 1). To establish face
validity, items were reviewed by experts from the field i.e.,
psychologists (MS, NGAK, AAK) and endocrinologists
(NRB, AMP). In order to confirm the content and face
validity (i.e., relevance, comprehensibility and acceptabil-
ity of the items), cognitive debriefing interviews with 4
patients were conducted by the investigator (CDA).
Validated questionnaires to test concurrent validity
Generic QOL questionnaires
EuroQoL-5D (EQ-5D) assesses the current health status
reflected in five health dimensions: mobility, self-care,
usual activities, pain/discomfort, and anxiety/depression.
Scores are expressed on a 1–3 scale per dimension, with
higher scores indicating worse QoL. The questionnaire also
includes a visual analogue scale (VAS) ranging from 0 to
100 for recording an individual’s rating of their current
health-related well-being, with higher scores indicating a
better health status. The EQ-5D was found to be reliable
and valid [21].
MOS Short Form 36 (SF-36) assesses functional status
and general well-being during the previous month. The
items cover nine health concepts: (1) physical functioning,
(2) social functioning, (3) role limitation (physical), (4)
role limitation (emotional), (5) mental health, (6) vitality,
(7) pain, (8) general health perception, and (9) general
perception of change in health. Scores are expressed on a
0–100 scale, and higher scores indicate a better QoL. The
SF-36 has been found to be reliable and valid [22, 23].
Domain-specific QoL questionnaires
Multidimensional Fatigue Inventory (MFI-20) assesses
fatigue, using a five-point scale. Five different dimensions
can be calculated: (1) general fatigue, (2) physical fatigue,
(3) reduced activity, (4) reduced motivation, and (5) mental
fatigue. Scores vary from 0 to 20; with higher scores
indicating greater fatigue. The MFI-20 yields adequate
levels of reliability and validity [24].
Hospital Anxiety and Depression Scale (HADS) assesses
anxiety and depressive symptoms and consists of 14 items
on a 4-point scale, and both anxiety (7 items) and
depression (7 items) scores range from 0 to 21 points.
Higher scores indicate more severe anxiety and/or
depressive symptoms. A score [8 points on one of the
subscales is being used to indicate patients as being anx-
ious or depressed respectively [25]. The HADS yields
adequate levels of reliability and validity [26, 27].
Disease-specific QoL questionnaires
AcroQoL assesses acromegaly-related QoL and consists of
22 questions on a five-point scale. Three different dimen-
sions can be calculated: (1) physical score, (2) psycho-
logical-appearance, (3) psychological-personal relations,
and a total score. Lower scores indicate worse QoL. The
AcroQoL was found to be reliable and valid [11–13].
CushingQoL assesses Cushing-related QoL and consists
of 12 questions on a five-point scale. The total score ranges
from 12 to 60, with a lower score indicating worse QoL.
The CushingQoL yields adequate levels of reliability and
validity [10, 28].
Statistics
In order to assess the construct validity of the LBNQ-Pi-
tuitary, an exploratory factor analysis was performed on all
items using the Bothered by (Bb) scores (n = 49). We
conducted exploratory factor analysis using oblique rota-
tion. To check for multicollinearity the correlation matrix
was studied. The Kaiser–Meyer–Olkin (KMO) measure
was used to test for sampling adequacy. KMO can range
from 0 to 1, with values near 0 indicating diffusion in the
pattern of correlations, and values near 1 indicating com-
pact patterns of correlation. Internal consistency of the
LBNQ-Pituitary dimensions was measured using Cron-
bach’s alpha coefficients.
To establish concurrent validity correlations between Bb
scores and scores on the other questionnaires were calcu-
lated. Pearson’s correlations were calculated when data
were normally distributed and Spearman’s correlations
were calculated when data were not normally distributed.
Correlation coefficients ranging from .10 to .30 indicate a
small effect, .30 to .50 a medium effect, and[.50 a large
effect. It was expected that scales that are conceptually
related correlate moderately to highly with one another
(convergent validity). Conversely, scales with a less clear
or absent conceptual relation are expected to show weak
correlations (divergent validity). In order to correct for
multiple testing the Bonferroni correction was applied and
the level of significance was set at P B .0001.
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Discriminant validity was examined by LBNQ-Pituitary
scores between the different pituitary diseases and by using
the HADS cut-off points (score[8 points). For the com-
parison between pituitary diseases an ANOVA was used
when data were normally distributed and a Kruskal–Wallis
Test was used when data were not normally distributed. For
the comparison between patients being clinically anxious
or depressed, independent sample t-tests were used when
data were normally distributed, and Mann–Whitney U tests
when data were not normally distributed. The level of
significance was set at P\ .05.
Results
Cognitive debriefing interviews
The LBNQ-Pituitary was completed by four patients in the
presence of the investigator (CDA) (3 men and 1 woman;
mean age: 57.5 ± 18.7 years). Patients were asked to fill-
out the questionnaire and were asked about their thoughts
about the questions and whether they thought items were
missing. Patients agreed with the items and found it rele-
vant that attention was being paid to the psychosocial
consequences of their disease. The LBNQ-Pituitary proved
to be feasible and there were no cues for missing items.
Only question 49 (‘As a consequence of my pituitary
condition, I experience difficulties in performing my
work’) was adapted by adding the answer option ‘‘Not
applicable’’.
Patient characteristics (Table 1)
The full survey was completed by 337 patients (61 %
females). The mean age of patients was 56.8 ± 13.7 years
with a mean duration since diagnosis of 15.3 ± 11.4 years.
Frequency of reported bother and needs for support
(Table 2)
The number of patients who reported to be bothered by a
certain complaint (i.e., ‘‘This problem and its consequences
bother me:’’ 3. Considerably or 4. Extremely) were coun-
ted, as well as the number of patients who reported a need
for support for a certain complaint (i.e., ‘‘I find attention
from my healthcare providers to be:’’ 3. Considerably
important or 4. Extremely important). Among the most
bothersome complaints, fatigue was mentioned by 63
patients (17 %), while a larger group reported need for
support regarding fatigue from their healthcare providers
(25 %).
Construct validity and reliability analysis (Table 3)
Of the initial 49 items, after factor analyses 26 items
remained (see Supplement 2 for a detailed description). A
factor structure with five factors with eigenvalues over
Kaiser’s criterion 1 and a total explained variance of
58.5 % fitted the data best. The KMO measure of sampling
adequacy was 0.94 indicating adequate fit for factor anal-
ysis (i.e., the data are likely to factor well) [29]. Cronbach
alpha’s were calculated for each factor, and all factors were
found to be reliable (Cronbach’s alpha .765, or higher).
All items that fell out during factor analyses were
inspected (n = 23). Some items appeared to be of interest
only for a subset of subjects, for instance, ‘Deteriorated
partner relationship’, ‘Worries not being able to have
children’ and ‘Feeling to fail in care for family’ and were
kept as optional items for these subjects. Furthermore,
some items appeared rather disease specific, and of sig-
nificant interest for the respective diseases; ‘Difficulties
letting go of certain thoughts’, ‘Jealousy’, ‘Trouble
accepting’, ‘Sleeping problems’, ‘Sadness’ and ‘Shame’
were more relevant to patients with CD, whereas ‘Negative
thoughts about medication’ turned out to be more relevant
to patients with PRL, and ‘Impaired eyesight’ more rele-
vant to patients with NFA. Therefore, these items (n = 8)
were retained in the questionnaire and added as optional
questions for patients with CD, PRL or NFA. The sum
scores of the subscales were all transformed to a 0–100
scale. The final LBNQ-Pituitary consisted of 26 items,
which can be extended by three optional items being rel-
evant for a subset of patients and eight optional items being
relevant for a specific pituitary condition. For an overview
of retained items see Supplement 3.
Concurrent validity (Table 4)
As expected, a higher Bb score on Mood problems was
strongly associated with worse mood on the EQ-5D, as
well as with more anxiety and more depressive symptoms
(HADS) (convergent validity). On the other hand, a higher
Bb score on Mood problems was also strongly associated
with more impairment in social functioning (SF-36) (less
divergent validity). Furthermore, in patients with CD a
higher Bb on Mood problems was strongly associated with
worse disease-specific QoL.
A higher Bb score on Negative illness perceptions was
strongly associated with more impairment in social func-
tioning (SF-36), more anxiety and a higher total score on
the HADS. In patients with CD a higher Bb score on
Negative illness perceptions was strongly associated with
worse disease-specific QoL.
296 Pituitary (2016) 19:293–302
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A higher Bb score on Issues in sexual functioning was
associated with more impairment in disease-specific QoL
in patients with CD and in patients with ACRO (i.e.,
AcroQoL, except subscale Psychological appearance).
As expected, a higher Bb score on Physical and Cog-
nitive complaints was strongly correlated with more
impairments in the performance of daily activities (EQ-
5D), worse general well-being (VAS EQ-5D), more
impairments in physical functioning, more physical role
limitations, and more pain (SF-36) (convergent validity).
On the other hand, a higher Bb score on Physical and
Cognitive complaints was also strongly associated with
more impairment in social functioning, more emotional
role limitations (SF-36), more anxiety and more depressive
symptoms (HADS) (less divergent validity). In addition, it
was associated with worse disease-specific QoL in patients
with CD and in patients with ACRO (i.e., AcroQoL
Physical score and Total score) (convergent validity),
whereas no significant correlations were found with the
AcroQoL subscales Psychological-appearance and Psy-
chological-personal relations (divergent validity).
As expected, a higher Bb score on Issues in social
functioning was strongly associated with more impairment
in social functioning (SF-36) (convergent validity),
whereas also high associations were found with physical
and emotional role limitations (SF-36). Furthermore, a
higher Bb score on Issues in social functioning was highly
associated with more depressive symptoms and a higher
Table 1 Patient characteristics
Total (n = 337) CD (n = 72)a ACRO (n = 76) PRL (n = 92) NFA (n = 97)
Gender (M/F) 131/206 16/56 38/38 23/69 54/43
Age (years) 56.8 (13.7) 54.5 (12.6) 60.6 (13.1) 50.7 (13.3) 61.3 (13.0)
Education [n (%)]
Low 108 (32 %) 25 (35 %) 33 (43 %) 22 (24 %) 28 (29 %)
Medium 97 (29 %) 20 (28 %) 21 (28 %) 27 (29 %) 29 (30 %)
High 132 (39 %) 27 (37 %) 22 (29 %) 43 (47 %) 40 (41 %)
Marital status [n (%)]
Single 43 (13 %) 11 (15 %) 7 (9 %) 15 (16 %) 10 (10 %)
Relationship/marriage 262 (78 %) 52 (72 %) 62 (82 %) 68 (75 %) 80 (83 %)
Divorced 17 (5 %) 7 (10 %) 3 (4 %) 5 (5 %) 2 (2 %)
Widow 15 (4 %) 2 (3 %) 4 (5 %) 4 4 %) 5 (5 %)
Pituitary surgery [n (%)] 228 (68 %) 53 (74 %) 68 (90 %) 26 (28 %) 81 (84 %)
Radiotherapy [n (%)] 76 (23 %) 22 (31 %) 19 (25 %) 10 (11 %) 25 (26 %)
Duration of follow-up (years) 15.3 (11.4) 16.2 (13.6) 18.7 (10.6) 16.1 (10.5) 11.3 (10.1)
Medical treatment for the pituitary diseaseb 231 (69 %) 49 (68 %) 52 (68 %) 61 (66 %) 69 (71 %)
CD Cushing’s disease, ACRO acromegaly, PRL prolactinoma, NFA non-functioning pituitary adenoma
a 21 patients were diagnosed with adrenal Cushing’s syndrome, of whom 12 were treated with bilateral adrenalectomy and 10 were treated with
unilateral adrenalectomy
b Hormonal replacement therapy and/or suppressant medication
Table 2 Top-10 highest
bothers and needs for support
: Highest bothered by (Bb) n (%) : Highest needs for support (NfS) n (%)
Fatigue 63 (17) Fatigue 84 (25)
Difficulties in performing work 42 (12) Afraid that pituitary tumour will recur 68 (20)
Problems concentrating 37 (11) Worried about physical symptoms 65 (19)
More sensitive to stressful situations 35 (10) Problems concentrating 62 (18)
Pain 35 (10) Less interested in sex 55 (16)
Going beyond own limits 34 (10) Mood swings 55 (16)
Less interested in sex 34 (10) Memory problems 54 (16)
Physical problems during sex 34 (10) Difficulties in performing work 52 (15)
Sleeping problems 34 (10) More sensitive to stressful situations 51 (15)
Difficulties letting go of certain thoughts 33 (10) Sleeping problems 50 (15)
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total score on the HADS (less divergent validity). In
addition, it was associated with worse disease-specific QoL
in patients with CD and patients with ACRO (i.e., Acro-
QoL all subscales).
Finally, a higher total Bb score was strongly associated
with more impairment in daily activities, worse mood (EQ-
5D), worse general well-being (VAS EQ-5D), more
impairment in social functioning, more physical and
emotional role limitations, and more pain (SF-36). Like-
wise, a higher total Bb score was associated with more
anxiety and more depressive symptoms (HADS). In addi-
tion, a higher Bb total score was associated with worse
disease-specific QoL in patients with CD and patients with
ACRO (i.e., AcroQoL, except subscale Psychological
appearance).
Discriminant validity
Between different pituitary diseases
Patients with CD reported a higher Bb and NfS score on
Physical and Cognitive complaints compared to the other
groups (ACRO, PRL, NFA) (P = .004 and P = .043,
respectively). Furthermore, patients with CD reported a
Table 3 Results of final factor analysis existing of 26 items
Item (item no.) Mood
problems
Negative illness
perceptions
Issues in sexual
functioning
Physical and
cognitive
complaints
Issues in social
functioning
More easily irritated (20) .780 .058 .097 -.074 .034
Changes in personality (18) .595 -.137 .098 -.091 .120
Emotional reactions have changed (19) .585 -.011 .027 -.219 .049
Mood swings (12) .584 -.128 .091 -.125 .022
Anger (23) .491 -.220 -.033 .056 .227
Panic (13) .319 -.078 -.079 -.204 .224
Negative thoughts about how condition will progress
(37)
-.028 2.809 -.018 -.040 .081
Negative thoughts about the extent to which the
condition can be kept under control (38)
-.109 2.756 .043 -.029 .163
Negative thoughts about the consequences of the
condition (36)
.135 2.678 -.050 -.027 .054
Worried about physical symptoms (16) .218 2.537 .070 -.168 -.021
Afraid that pituitary tumour will recur (17) .240 2.438 .159 .089 -.004
Less interested in sex (41) .010 .040 .822 -.063 -.056
Physical problems during sex (40) -.017 .017 .783 .018 .114
Guilt towards partner/close family (26) .200 -.170 .305 -.051 .193
Problems concentrating (6) .079 .066 .010 2.766 .097
Memory problems (8) .114 .152 -.010 2.704 .127
Fatigue (1) -.023 -.108 .185 2.694 -.096
Difficulties in doing several things at the same time
(7)
.076 .015 .048 2.644 .137
Pain (2) -.134 -.365 .028 2.501 .022
Going beyond own limits (33) .167 -.135 .052 2.461 -.003
Changes in physical appearance (3) .093 -.174 .052 2.358 .036
Circle of friends has become smaller (45) -.127 -.017 .085 .027 .847
Loneliness (25) .195 -.051 -.087 -.110 .682
Feeling uncomfortable in social situations (46) .058 -.073 .046 .001 .620
Lack of understanding of the consequences of the
condition from people in social circle (47)
.074 -.028 .025 -.130 .548
Feeling the need to be alone (30) .260 -.038 .089 -.092 .421
Cronbach’s alpha .889 .861 .765 .876 .862
Factor loadings in bold
a: Cronbach’s alpha coefficient
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higher Bb score on Issues in Social functioning, as well as a
higher Bb Total score compared to patients with PRL
(P = .004 and P = .023, respectively). In addition,
patients with CD reported a higher NfS score on Issues in
Social functioning, as well as Total NfS compared to
patients with ACRO (P = .012 and P = .034, respec-
tively) (Supplement 4). On all other subscales of the
LNBQ-Pituitary no significant differences were found,
pointing to a considerable overlap in perceived conse-
quences between pituitary diseases.
Cut-off scores HADS (Fig. 1a, b)
Based on the clinically used cut-off score of the HADS it
was observed that 47 patients (14 %) were clinically anx-
ious and 45 (13 %) were clinically depressed. Based on this
Table 4 Significant correlations between Bothered by scores on the subscales of the LBNQ-Pituitary and QoL measures
Mood
problems
Negative illness
perceptions
Issues in sexual
functioning
Physical and cognitive
complaints
Issues in social
functioning
Total
Bb
EQ-5D
Mobility .261 .297 .236 .275
Selfcare .232 .214 .221
Daily activity .387 .459 .304 .547 .449 .534
Pain .302 .369 .480 .337 .421
Mood .499 .440 .340 .422 .427 .501
VAS (well-being) -.496 -.482 -.335 2.596 -.413 2.599
SF-36
Physical functioning -.358 -.433 -.244 2.518 -.418 -.483
Social functioning 2.599 2.534 -.414 2.629 2.662 2.690
Role limitations
physical
-.457 -.489 -.329 2.639 2.530 2.611
Role limitations
emotional
-.492 -.406 -.328 2.569 2.531 2.561
Mental health -.247 -.209 -.220
Vitality -.252 -.289 -.264
Pain -.372 -.432 -.240 2.559 -.436 2.505
General health -.220 -.257 -.248
Health change
MFI-20
General fatigue
Physical fatigue
Reduced activity
Reduced motivation -.220 -.245 -.220 -.265
Mental fatigue
HADS
Anxiety .598 .552 .389 .530 .471 .612
Depression .576 .493 .458 .632 .565 .670
Total score .659 .572 .469 .649 .573 .716
CushingQoL 2.696 2.661 2.675 2.873 2.802 2.884
AcroQoL
Physical score 2.513 2.705 2.586 2.661
Psychological-
appearance
2.509
Psychological-personal
relations
2.593 2.525 2.563
Total score 2.533 2.575 2.644 2.613
All Spearman’s correlations, P B .0001. Empty cells: correlation was not significant. Bold: correlations (r C .500)
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observation, groups were formed (anxious vs. not anxious;
depressed vs. not depressed) and the scores on the Bb
subscales of the LBNQ-Pituitary were compared between
groups. It was found that patients who could be classified
as anxious and/or depressed ([8 points on HADS subscales
respectively) showed higher scores on all Bb subscales, as
well as the Bb Total score (P B .0001).
Discussion
The present study demonstrated that the resultant factors
derived from the exploratory factor analysis of the Both-
ered by (Bb) items of the LBNQ-Pituitary were in accor-
dance with the themes discussed in the focus group
conversations i.e., mood problems, negative illness per-
ceptions, issues in sexual functioning, physical and cog-
nitive complaints, and issues in social functioning [15].
Internal consistency of these underlying dimensions was
supported by high Cronbach’s alphas. Convergent validity
was observed for the subscales Mood problems, Physical
and Cognitive complaints and Issues in social functioning.
Although divergent validity was also observed by no or
weaker correlations with incongruous subscales, some
strong correlations were observed between these LBNQ-
Pituitary subscales and non-corresponding subscales, such
as the strong correlation between Bb subscale Mood
problems and Social functioning (SF-36). Furthermore, the
LBNQ-Pituitary showed good discriminant validity
between patients with various pituitary disease (e.g.,
patients with CD reported a higher score on Bb and NfS
subscales compared to the other groups) and between
patients being anxious or depressed as determined by the
scores on the HADS.
Based on the results of our recent focus group study [15]
it was assumed that physical and cognitive complaints
would be identified as two separate dimensions. Surpris-
ingly, in the present study physical complaints and cogni-
tive complaints both loaded on one factor. A possible
explanation might be that the question assessing fatigue
was not explicitly divided into physical fatigue and mental
fatigue. We speculate that specifying this item in future
research, might result in fatigue being represented in two
factors.
The subscale Negative illness perceptions showed
strong correlations with social functioning (SF-36) and
anxiety (HADS). These correlations could be explained by
previous literature showing that illness perceptions con-
tribute to QoL in patients with pituitary disease [30, 31],
and in other patient populations [32, 33]. Furthermore, the
subscale Issues in sexual functioning showed strong cor-
relations with disease-specific QoL (i.e., CushingQoL,
AcroQoL), whereas only small to moderate associations
were found with generic QoL measures. This is probably
explained by the fact that both disease-specific QoL mea-
sures include items about sexuality, whereas the generic
measures do not assess sexuality. This observation points
to convergent validity of this subscale. Furthermore, it
could be observed that scores on the LBNQ-Pituitary cor-
relate highly with outcomes on the disease-specific ques-
tionnaires, which supports the convergent validity in terms
of disease specificity.
The observation that strong correlations were observed
between incongruous subscales, could possibly be
explained by the tight connections between the domains of
the biopsychosocial model [34], such as that mood prob-
lems might also result in less social functioning. Surpris-
ingly, the LBNQ-Pituitary showed only weak correlations
with the Multidimensional Fatigue Inventory-20. This
might also be explained by the fact that fatigue was
assessed with just one item in the present version of the
LBNQ-Pituitary.
Furthermore, the disease-specific bother of pituitary
adenomas observed in this study is in accordance with
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Fig. 1 a Bothered by scores of patients with versus without anxiety.
b Bothered by scores of patients with versus without depression.
Median and inter quartile range (IQR). HADS-A Anxiety subscale of
the Hospital Anxiety and Depression Scale, HADS-D Depression
subscale of the Hospital Anxiety and Depression Scale, MP mood
problems, NIP negative illness perceptions, ISeF issues in sexual
functioning, PC physical and cognitive complaints, ISoF issues in
social functioning, Tot total score
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previous literature, with patients with CD reporting the
largest negative impact on QoL [7, 35, 36]. The LBNQ-
Pituitary offers the possibility to assess bother and needs
for support in people with pituitary disease in general with
potential comorbid hypopituitarism, while it can also be
used to assess aspects related to specific pituitary disease,
such as CD or PRL. Moreover, since there are no ques-
tionnaires available for patients with NFA or PRL, the
LBNQ-Pituitary can be used in these patient groups.
To the best of our knowledge, no work has been pub-
lished reporting a similar questionnaire to the LBNQ-Pi-
tuitary which can assess to which extent patients are
bothered by consequences of the disease, as well as their
needs for support. We postulate that this questionnaire will
provide valuable information, in addition to already
available QoL data, which is needed for the improvement
of psychosocial care in patients with pituitary disease.
Furthermore, the LBNQ-Pituitary can be used by clinicians
to distinguish between specific bothers and/or specific
needs for support. Awareness of patients’ needs for support
could facilitate the translation from patients’ needs to
optimal patient care. For an overview of the distribution of
reported needs for support in our cohort, see Fig. 2. Con-
sidering the fact that unmet needs are found to influence
QoL [37], and that patients with pituitary disease previ-
ously reported unmet needs (e.g., ‘‘better cooperation and
communication between medical specialties’’, ‘‘absence of
recognition for certain complaints’’) [15], we postulate that
paying attention to patients’ needs for support will posi-
tively affect QoL.
In conclusion, the LBNQ-Pituitary can be used to assess
whether patients are bothered by the consequences of the
disease, as well as their needs for support. Nevertheless,
future research is needed to further establish the psycho-
metric properties, for instance by the use of a confirmatory
factory analysis in another cohort in the Netherlands, but
also in patients from a different country and with a dif-
ferent language. The LBNQ-Pituitary can be used in clin-
ical research (e.g., to compare bother and needs for support
between groups, to evaluate the effect of interventions
regarding bother and needs). It can also be used to facilitate
the efficient assessment of bother and needs for support in
patients with pituitary disease in clinical practice, and
further research into this area is warranted.
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